{"id":"W2313308264","doi":"10.1097/mib.0000000000000720","title":"O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohnʼs Disease Refractory to Anti-TFNα","year":2016,"lang":"en","type":"article","venue":"Inflammatory Bowel Diseases","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":47,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; Robarts Clinical Trials","funders":"","keywords":"Medicine; Ustekinumab; Placebo; Refractory (planetary science); Internal medicine; Clinical endpoint; Gastroenterology; Crohn's disease; Adverse effect; Randomization; Dosing; Randomized controlled trial; Antagonist; Intention-to-treat analysis; Disease; Infliximab; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000447857,0.000893676,0.0009002915,0.0005451168,0.0002564964,0.0001176875,0.001010332,0.0002685572,0.0003125139],"category_scores_gemma":[0.0003460015,0.0007551237,0.0003999427,0.0002364616,0.0001643821,0.00009954438,0.0005611585,0.0002000886,0.000136918],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001714503,"about_ca_system_score_gemma":0.0005753711,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001064357,"about_ca_topic_score_gemma":0.001528721,"domain_scores_codex":[0.9945611,0.0005953671,0.0015564,0.001452494,0.0008148831,0.001019795],"domain_scores_gemma":[0.9956204,0.00009478021,0.0005949636,0.001911143,0.0005195956,0.001259063],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.3953657,0.0103923,0.5121178,0.0006224453,0.0007706307,0.002844889,0.0006705246,0.001646335,0.07394493,0.00009383544,0.001148303,0.0003823003],"study_design_scores_gemma":[0.2742855,0.0006769957,0.7180349,0.0004661591,0.0005791361,0.000003993481,0.0006507616,0.0003090806,0.001724885,0.0000653684,0.001603197,0.001599976],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9930274,0.0002740611,0.00002596939,0.0001139751,0.0002877309,0.005194101,0.0007418119,0.0001212164,0.0002137151],"genre_scores_gemma":[0.9963776,0.00003937123,0.00002065345,0.0004280798,0.00036963,0.001870317,0.0002048558,0.0001681594,0.0005212576],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2059171,"threshold_uncertainty_score":0.99949,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01905318042425172,"score_gpt":0.2829108564889205,"score_spread":0.2638576760646688,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}